¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"occlusal analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • qualitative analysis
    Á¤¼ººÐ¼®
  • quantitative analysis
    Á¤·®ºÐ¼®
  • radiochemical analysis
    ¹æ»çÈ­Çкм®
  • radiometric analysis
    ¹æ»ç¼±°èÃøºÐ¼®
  • regression analysis
    ȸ±ÍºÐ¼®
  • risk benefit analysis
    À§ÇèÆíÀͺм®
  • Southern blot analysis
    ¼­´øºí·ÔºÐ¼®
  • statistical analysis
    Åë°èºÐ¼®
  • survival analysis
    »ýÁ¸ºÐ¼®
  • system analysis
    °èÅëºÐ¼®
  • self-analysis
    ÀÚ±âºÐ¼®
  • sequential analysis
    ¼øÂ÷ÀûºÐ¼®, ÀϷúм®
  • situation analysis
    »óȲºÐ¼®
  • Western blot analysis
    ¿þ½ºÅϺí·ÔºÐ¼®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • statistical analysis
    Åë°èºÐ¼®
  • survival analysis
    »ýÁ¸ºÐ¼®
  • system analysis
    °èÅëºÐ¼®
  • training analysis
    ±³À°ºÐ¼®
  • meta-analysis
    ¸ÞŸºÐ¼®
  • precipitation analysis titration
    ħÀüºÐ¼®ÀûÁ¤
  • self-analysis
    ÀÚ±âºÐ¼®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • clonal analysis
    Ŭ·ÐºÐ¼®, ¹«¸®ºÐ¼®
  • cluster analysis
    ±ÕÁÖ±ººÐ¼®(¡­ÝÂà°).
  • colo(u)rimetric analysis
    ºñ»öºÐ¼®¹ý(ÝïßäÝÂà°Ûö).
  • combustion analysis
    ¿¬¼ÒºÐ¼®(¡­ÝÂà°).
  • computer-assisted semen analysis (CASA )
    ÄÄÇ»ÅÍ º¸Á¶ Á¤¾×ºÐ¼®
  • computerized image analysis
    ÄÄÇ»ÅÍ ¿µ»ó ºÐ¼®
  • configurational analysis
    ¹èÄ¡ºÐ¼®(ÛÕöÇÝÂà°)
  • cost-benifit analysis
    ºñ¿ë-ÆíÀͺм®.
  • cost-effectiveness analysis
    ºñ¿ë-È¿°úºÐ¼®.
  • cost-efficiency analysis
    ºñ¿ë-È¿À²ºÐ¼®.
  • decision analysis
    °áÁ¤<°á´Ü>ºÐ¼®
  • displacement analysis
    ÀüÀ§ºÐ¼®
  • distributive analysis
    ºÐÆ÷ºÐ¼®(ÊÙËÓËÛ).
  • elementary analysis
    ¿ø¼ÒºÐ¼®(¡­ÝÂà°).
  • endgroup analysis
    ¸»´Ü±âºÐ¼®(ØÇÓ®ÐñÝÂà°).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ANAL, anal analgesia, analgesic; analysis, analytic
ANCOVA analysis of covariance
ANOV, ANOVA analysis of variance
AVA activity vector analysis; antiviral antibody; aortic valve area; aortic valve atresia; arteriovenous...
BIA biolectric impedance analysis; bioimmunoassay
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
DIA Digital image analysis
DFA Discriminant Function Analysis
DA Discriminant analysis
DMA Dynamic Mechanical Analysis
ESCA Electron Spectroscopy for Chemical Analysis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • occlusal balance
    ±³ÇÕ ±ÕÇü
    1. ¾Ç°ñÀÇ ±â´É ¿îµ¿ ½Ã¿¡ ÀÇÄ¡°¡ À̵¿µÇÁö ¾Êµµ·Ï ÇÏ´Â ±³ÇÕ Á¢ÃË. 2. ±â´É ¹üÀ§ ³»¿¡¼­ÀÇ ºñÁß½ÉÀ§ ¿îµ¿À» ÇÏ´Â µ¿¾È ´ëÇÕÇÏ´Â Ä¡±ÃÀÇ ¾çÃø ¸é¿¡¼­ ´ëÇÕÄ¡³ª Ä¡¾Æ À¯»ç¹°ÀÇ Á¢ÃËÀÌ µ¿½Ã¿¡ ÀϾ ¼ö ÀÖ´Â Á¶°Ç.
  • occlusal caries
    ±³ÇÕ¸é ¿ì½ÄÁõ, ±³ÇÕ¸é ¿ì½Ä
  • occlusal clearance
    ±³ÇÕ °£°Ý
  • occlusal contact
    ±³ÇÕ Á¢ÃË
    µ¿ÀǾî=occlusion.
  • occlusal correction
    ±³ÇÕ ¼öÁ¤
    ºÎÁ¤ ±³ÇÕÀ» ¼öÁ¤ÇÏ´Â °Í°ú ±³ÇÕ¸éÀÇ ±ÕÇüÀ» ÀÌ·çÁö ¸øÇÏ´Â ±³ÇÕ Á¢ÃËÀ» Á¦°ÅÇÏ´Â °Í.
  • occlusal curve
    ±³ÇÕ ¸¸°î
    ±³ÇÕ¸éÀÌ ³õÀÌ°Ô µÇ´Â ÀüµÎ¸é°ú ½Ã»ó¸é »óÀÇ Ä¡¿­ÀÇ ¸¸°î.
  • occlusal discrepancy
    ±³ÇÕ ºÎÁ¶È­
  • occlusal disharmony
    ±³ÇÕ ºÎÁ¶È­, ±³ÇÕ Àå¾Ö
    ´ëÇյǴ ±³ÇÕ¸é°úÀÇ Á¢ÃËÀÌ ´Ù¸¥ Ä¡¾ÆÀÇ ±³ÇÕ °ü°è ȤÀº µÎ°³ ÇÏ¾Ç º¹ÇÕüÀÇ ÇØºÎÇÐÀû »ý¸®ÇÐÀû ±¸¼º ¼ººÐµé°ú Á¶È­¸¦ ÀÌ·çÁö ¸øÇÏ´Â Çö»ó.
  • occlusal dovetail
    ±³ÇÕ¸é ±¸¹ÌÇü
    ÀÎÁ¢¸é ¿Íµ¿ÀÇ ±³ÇÕ¸é °è´Ü Á¾¸»ºÎ¿¡ ÁÖ´Â ±¸¹ÌÇüÀÌ´Ù.
  • occlusal edge
    ±³ÇÕ¿¬
  • occlusal equilibration
    ±³ÇÕ Á¶Á¤, ±³ÇÕ ÆòÇü
    º¸Åë ¼öÁ÷ ±³Çշ°ú Ãø¹æ ±³ÇÕ·ÂÀ» ´õ¿í ±ÕÀÏÇÏ°Ô ºÐÆ÷½Ã۱â À§ÇØ ¿¬¸¶ ±â±¸¸¦ »ç¿ëÇÏ¿© Ä¡¾ÆÀÇ Ä¡°ü ºÎÀ§¸¦ Á¶Á¤ÇÏ´Â °Í.
  • occlusal film
    ±³ÇÕ Çʸ§
  • occlusal form
    ±³ÇÕ ÇüÅÂ
    Ä¡¾Æ³ª Ä¡¿­ÀÇ ±³ÇÕ¸éÀÇ ÇüÅÂ.
  • occlusal guidance
    ±³ÇÕ À¯µµ
    Æí½É ¿îµ¿¿¡¼­ ÇϾÇÀÌ Ä¡¾Æ¿¡ ÀÇÇØ °áÁ¤µÇ´Â À¯µµ·Î¼­ Ä¡¾Æ´Â Á¢ÃËÇÑ »óÅ·ΠÀ¯ÁöµÈ´Ù.
  • occlusal inclined plane
    ±³ÇÕ °æ»çÆÇ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
cephalometric analysis A study of the skeletal and dental relationships used in orthodontic case analysis.
(05 Mar 2000)
percept analysis Psychologic survey of an individual's personality using Rorschach's series of inkblots.
(05 Mar 2000)
character analysis Analysis of the defenses and personality traits that characterise an individual.
(05 Mar 2000)
meta-analysis <statistics> A quantitative method of combining the results of independent studies (usually drawn from the published literature) and synthesizing summaries and conclusions which may be used to evaluate therapeutic effectiveness or to plan new studies.
With application chiefly in the areas of research and medicine. It is often an overview of clinical trials. It is usually called a meta-analysis by the author or sponsoring body and should be differentiated from reviews of the literature.
(27 Jun 1999)
cluster analysis A set of statistical methods used to group variables or observations into strongly inter-related subgroups. In epidemiology, it may be used to analyze a closely grouped series of events or cases of disease or other health-related phenomenon with well-defined distribution patterns in relation to time or place or both.
(12 Dec 1998)
Western blot analysis A procedure in which proteins separated by electrophoresis in polyacrylamide gels are transferred (blotted) onto nitrocellulose or nylon membranes and identified by specific complexing with antibodies that are either pre-or post-tagged with a labelled secondary protein.
See: immunoblot.
Synonym: Western blot, Western blotting.
Origin: coined to distinguish it from eponymic Southern blot a.
(05 Mar 2000)
combustion analysis <technique> A method for determining the chemical composition of a compound by burning the compound under controlled conditions. Often used to determine the relative amounts of carbon and hydrogen in a compound.
(09 Oct 1997)
multivariate analysis A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
(12 Dec 1998)
content analysis Any of a variety of techniques for classification and study of the verbal products of normal or of psychologically disabled individuals.
(05 Mar 2000)
cost-benefit analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
(12 Dec 1998)
costs and cost analysis Absolute, comparative, or differential costs pertaining to services, institutions, resources, etc., or the analysis and study of these costs.
(12 Dec 1998)
half-tetrad analysis <genetics> The analysis of tetrad chromosomes (a pair of homologous chromosomes, thus four total chromosomes) after recombination when only half of the tetrad (two of the four chromosomes) can be analysed.
(13 Nov 1997)
predisposition analysis <genetics> The analysis of how some people are more likely to get certain diseases as a result of their genetic make-up.
(31 Dec 1997)
saturation analysis General term for an assay in which a binder competes for labelled versus unlabelled ligand; following separation of free and bound ligand, the ligand (the analyte assayed) is quantitated by relating bound and unbound ratios to known standards.
See: enzyme-linked immunosorbent assay, radioreceptor assay, immunoassay, enzyme-multiplied immunoassay technique, radioimmunoassay.
Synonym: displacement analysis, saturation analysis.
(05 Mar 2000)
proximate analysis An analysis which reports volatile matter, fixed carbon, moisture content, and ash present in a fuel as a percentage of dry fuel weight.
(05 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á